[October 20, 2004] Positron Corporation Installs PET Scanner at Decatur Health Imaging, LLC HOUSTON --(Business Wire)-- Oct. 20, 2004 -- Positron Corporation (OTCBB:POSC), manufacturer of positron emission tomography (PET) scanners, delivered and installed a Positron PET Scanner to Decatur Health Imaging, LLC located in Decatur, Alabama. This transaction will be recorded in the company's third fiscal quarter financial results. Dr. Gregory S. Windham, Managing Member of Decatur Health Imaging, stated, "I have been very pleased with the performance and accuracy of our existing Positron PET scanner. Our expansion into the Decatur area will provide patients with the highest quality PET imaging at our dual modality center without requiring patients to travel outside of their local community. We will be providing cardiac and oncological imaging services and look forward to developing our neurology practice. As our population ages, dementia disorder diagnosis will become increasingly important, along with the significant benefits to early detection of heart disease, the number one cause of death in America. Physicians and patients demand state-of-the-art technology and will receive it at our center." Decatur Health Imaging is a free-standing, physician owned imaging center which provides comprehensive cardiac, oncological and neurological imaging services to patients and physicians in the Decatur, Alabama area. The center collaborates closely with Decatur General Hospital and its cancer treatment center. Gary Brooks, President and CEO of Positron said, "We are delighted that Dr. Windham has chosen a second Position scanner in addition to the system in Cullman, Alabama for installation at Decatur Health Imaging. Positron strives to provide the highest customer service to compliment the reliability and accuracy of our unique technology. Health Imaging's expansion into the Decatur area will fulfill the growing patient demand for the detail that only PET offers." Positron Corporation is primarily engaged in designing, manufacturing, marketing and supporting advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary technology for the diagnosis and treatment of patients in the areas of oncology, cardiology and neurology. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas - Houston Health Science Center, Hadassah Hebrew University Hospital in Jerusalem, Israel, The Coronary Disease Reversal Center in Buffalo, New York, Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at http://www.positron.com. Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein are forward-looking statements and, accordingly, involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company's expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including, without limitations, management's examination of historical operating trends, data contained in the Company's records and other data available from third parties, but there can be no assurance that management's expectations, beliefs or projections will result or be achieved or accomplished. In addition to other factors and matters discussed elsewhere herein, the following are important factors that, in the view of the Company, could cause actual results to differ materially from those discussed in the forward-looking statements: the ability of the Company to attain widespread market acceptance of its POSICAM(TM) systems; the ability of the Company to obtain acceptable forms and amounts of financing to fund future operations; demand for the Company's services; and competitive factors. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. [ Back To TMCnet.com's Homepage ]